Janux Therapeutics Inc. – Material Contracts Watch

from 10-Q 153 pages Exclusive License and Collaboration Agreement Dated as of January 21, 2026 by and Between Janux Therapeutics, Inc. and Bristol-Myers Squibb Company

from 10-Q 7 pages January 10, 2026 William Y. Go, M.D., PH.D. Re: Employment Terms Dear Will: Janux Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Anticipated to Begin on or Around January 26, 2026 (The “Start Date”). Position

from 10-Q 4 pages Janux Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-K 4 pages Janux Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-Q 7 pages April 8, 2025 Janeen Doyle Re: Employment Terms Dear Janeen: Janux Therapeutics, Inc. (The "Company") Is Pleased to Offer You Employment Anticipated to Begin on or Around May 12, 2025 (The "Start Date"). Position

from 10-Q 4 pages Janux Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-K 5 pages April 24, 2023 Zachariah McIver Re: Employment Terms Dear Zachariah: Janux Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Anticipated to Begin on or Around June 5, 2023 (The “Start Date”). Position

from 10-Q 13 pages August 2, 2024 Tighe Reardon Re: Transition and Consulting Agreement Dear Tighe: This Letter Sets Forth the Substance of the Transition and Consulting Agreement (The “Agreement”) That Janux Therapeutics, Inc. (The “Company”) Is Offering to You. 1

from 10-Q 4 pages Janux Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-Q 69 pages Janux Therapeutics, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: June 3, 2021 Approved by the Stockholders: June 4, 2021

from 10-K 7 pages The Compensation Committee (The “Compensation Committee”) of the Board of Directors (The “Board”) of Janux Therapeutics, Inc., a Delaware Corporation (The “Company”), Has Determined That It Is in the Best Interests of the Company and Its Stockholders to Adopt This Incentive Compensation Recoupment Policy (This “Policy”) Providing for the Company’s Recoupment of Recoverable Incentive Compensation That Is Received by Covered Officers of the Company Under Certain Circumstances. Certain Capitalized Terms Used in This Policy Have the Meanings Given to Such Terms in Section 3 Below. This Policy Is Designed to Comply With, and Shall Be Interpreted to Be Consistent With, Section 10d of the Exchange Act, Rule 10d-1 Promulgated Thereunder (“Rule 10d-1”) and NASDAQ Listing Rule 5608 (The “Listing Standards”). 2. Effective Date

from 10-K 4 pages January 1, 2021 Thomas Diraimondo Re: Employment Terms Dear Tommy: Janux Therapeutics, Inc. (The "Company") Is Pleased to Offer You Employment Beginning on January 1, 2021 (The "Start Date"). Position

from 10-K 3 pages Janux Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-K 3 pages February 8, 2021 Charles Winter via Electronic Mail Confidential Dear Charles, We Are Very Pleased to Extend to You the Offer of Employment for the Exempt Position of Senior Vice President, Cmc Reporting to Me, the Company’s President and Chief Executive Officer. the Following Outlines Your Offer of Employment: Start Date: March 22, 2021

from 10-K 10 pages November 8, 2022 Shahram Salek-Ardakani, PH.D. Re: Transition and Consulting Agreement Dear Shahram: This Letter Sets Forth the Substance of the Transition and Consulting Agreement (The “Agreement”) That Janux Therapeutics, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1

from 10-K 121 pages Torrey Plaza Lease Pacific Plaza Owner, L.L.C., a Delaware Limited Liability Company, as Landlord, and Janux Therapeutics, Inc., a Delaware Corporation, as Tenant Summary of Basic Lease Information

from 10-K 6 pages January 20, 2022 Byron Robinson, PH.D. Re: Employment Terms Dear Byron: Janux Therapeutics, Inc. (The "Company”) Is Pleased to Offer You Employment Anticipated to Begin on or Around March 1, 2022 (The “Start Date”). Position

from 10-K 13 pages May 4, 2021 Shahram Salek-Ardakani, PH.D. Re: Offer of Employment Dear Shahram: Janux Therapeutics, Inc. (The “Company”) Is Pleased to Offer You At-Will Employment in the Position of Chief Scientific Officer on the Terms and Conditions Set Forth in This Letter Agreement (The “Agreement”). 1

from 10-Q 28 pages Lease Between Utc Properties LLC and Janux Therapeutics, Inc. Lease

from S-1/A 3 pages May 4, 2021 Dr. Wayne Godfrey, MD via Electronic Mail Confidential Dear Dr. Wayne Godfrey, We Are Very Pleased to Extend to You the Offer of Employment for the Exempt Position of Chief Medical Officer, Reporting to Me, the Company’s Chief Executive Officer. the Following Outlines Your Offer of Employment